The GLP 1 Shortage Is Over. Mass Market Compounding Should Be, Too The recent shortage of glucagon like peptide 1 (GLP 1) medications left patients and healthcare providers struggling to find alternatives.
But as the crisis subsides, it's time to address a more pressing issue: mass market compounding.
This cost effective approach can provide affordable, high quality GLP 1 treatments, yet its widespread adoption is hindered by regulatory complexities.